Karyopharm Therapeutics (KPTI) Research & Development (2012 - 2025)

Karyopharm Therapeutics has reported Research & Development for 14 years, with the latest figure at $27.7 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 16.92% year-over-year to $27.7 million; the trailing twelve-month figure through Dec 2025 stood at $125.6 million (down 12.3% YoY), and the FY2025 full-year result was $125.6 million, down 12.3% from the prior year.
• Research & Development for Q4 2025 stood at $27.7 million, down from $30.5 million in the prior quarter.
• The five-year high for Research & Development was $45.8 million in Q3 2021, with the low at $27.7 million in Q4 2025.
• Historically, Research & Development has averaged $35.9 million across 5 years, with a median of $35.0 million in 2024.
• The largest YoY upside for Research & Development was 30.39% in 2022 against a maximum downside of 31.54% in 2022.
• Karyopharm Therapeutics' Research & Development stood at $44.0 million in 2021, then retreated by 29.7% to $30.9 million in 2022, then grew by 27.31% to $39.4 million in 2023, then dropped by 15.44% to $33.3 million in 2024, then declined by 16.92% to $27.7 million in 2025.
• The last three Research & Development figures came in at $27.7 million (Q4 2025), $30.5 million (Q3 2025), and $32.8 million (Q2 2025), per Business Quant data.